CAS NO: | 1449-05-4 |
包装 | 价格(元) |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | 18α-Glycyrrhetinic acid, a diet-derived compound, is an inhibitor ofNF-kBand an activator ofproteasome, which serves as pro-longevity and anti-aggregation factor in a multicellular organism. 18α-Glycyrrhetinic acid inducesapoptosis[1][2]. | ||||||||||||||||
IC50& Target[1][2] |
| ||||||||||||||||
体外研究 (In Vitro) | 18α-Glycyrrhetinic acid (18a-GA) markedly reduces LX-2 cell numbers by 14.8% and 31.2% after 48 h and 72 h of treatment, respectively (P< 0.05). 18α-Glycyrrhetinic acid also significantly increases the percentage of LX-2 cells in phase G0/G1 and decreases it in phase S after treated for 48 h and 72 h compare with the control group. 18α-Glycyrrhetinic acid increases apoptosis to 6.8% at 48 h, compare with control (2.5%), and at 72 h the percentages of apoptotic cells in control and the treatment groups are 3.1% and 15.6%, respectively, in LX-2 cells (P<0.01). Furthermore, 18α-Glycyrrhetinic acid induces expression of PPAR-γ and alters some cell cycle and apoptosis-related proteins. 18α-Glycyrrhetinic acid also inhibits NF-κB DNA-binding activity[1]. | ||||||||||||||||
体内研究 (In Vivo) | 18α-Glycyrrhetinic acid (18α-GA) treatment significantly enhances life span ofC. elegansstrains with the most effective concentration being 20 μg/mL. Results reveal a significant delay of paralysis upon 18α-Glycyrrhetinic acid treatment. 18α-Glycyrrhetinic acid treatment also confers a significant reduction of Aβ deposits[2]. | ||||||||||||||||
分子量 | 470.68 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C30H46O4 | ||||||||||||||||
CAS 号 | 1449-05-4 | ||||||||||||||||
中文名称 | 18-α-甘草次酸 | ||||||||||||||||
结构分类 |
| ||||||||||||||||
来源 |
| ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : 11.36 mg/mL(24.14 mM;Need ultrasonic) 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|